1. //
  2. Start
  3. //
  4. Publications
  5. B7-H1 Selectively Controls TH17 Differen...
  6. Output formats
  7. //

B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway

Research output: Journal contributions › Journal articles › Research › peer-review

Standard

B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway. / Herold, Martin; Posevitz, Vilmos; Chudyka, Daria et al.
In: Journal of immunology (Baltimore, Md. : 1950), Vol. 195, No. 8, 15.10.2015, p. 3584-3595.

Research output: Journal contributions › Journal articles › Research › peer-review

Harvard

Herold, M, Posevitz, V, Chudyka, D, Hucke, S, Groß, C, Kurth, F, Leder, C, Loser, K, Kurts, C, Knolle, P, Klotz, L & Wiendl, H 2015, 'B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway', Journal of immunology (Baltimore, Md. : 1950), vol. 195, no. 8, pp. 3584-3595. https://doi.org/10.4049/jimmunol.1402746

APA

Herold, M., Posevitz, V., Chudyka, D., Hucke, S., Groß, C., Kurth, F., Leder, C., Loser, K., Kurts, C., Knolle, P., Klotz, L., & Wiendl, H. (2015). B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway. Journal of immunology (Baltimore, Md. : 1950), 195(8), 3584-3595. https://doi.org/10.4049/jimmunol.1402746

Vancouver

Herold M, Posevitz V, Chudyka D, Hucke S, Groß C, Kurth F et al. B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway. Journal of immunology (Baltimore, Md. : 1950). 2015 Oct 15;195(8):3584-3595. doi: 10.4049/jimmunol.1402746

Bibtex

@article{45af2a1578604d948b5706e41b3f7e43,
title = "B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway",
abstract = "It is currently acknowledged that T H17 cells are critically involved in the pathogenesis of autoimmune diseases such as multiple sclerosis (MS). In this article, we demonstrate that signals delivered by the coinhibitory molecule B7-homologue 1 (B7-H1) via a B7-homologue 1 mouse-IgG2aFc (B7-H1-Ig) fusion protein nearly abolish T H17, but not T H1 and T H2, differentiation via direct interaction with the T cell. These effects were equally pronounced in the absence of programmed death-1 or B7.1 and B7.2 on the T cell side, thus providing clear evidence that B7-H1 modulates T cell differentiation via a novel receptor. Mechanistically, B7-H1 interfered with early TCR-mediated signaling and cytokine-mediated induction of the T H17-determining transcription factors retinoic acid-related orphan receptor g t and IFN regulator factor-4 in a programmed death-1 and B7-independent fashion. In an animal model of MS, active myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis, B7-H1-Ig exhibited a significant and long-lasting effect on disease severity upon administration during the first 5 d of the priming phase, which was accompanied by reduced T H17 responses in the periphery and within the CNS. Importantly, B7-H1-Ig was even capable of interfering with T cell encephalitogenicity when interaction with the T cells occurred after priming using an adoptive transfer experimental autoimmune encephalomyelitis model. In line with this, both naive human CD4 + T cells and differentiated T H17 effector cells from MS patients were highly sensitive toward B7-H1-Ig-mediated T H17 suppression. Together, we propose the existence of a novel B7-H1-mediated immune-regulatory pathway in T cells, which selectively limits murine and human T H17 cell responses and might be therapeutically exploited to control T H17-mediated autoimmunity. ",
keywords = "Chemistry",
author = "Martin Herold and Vilmos Posevitz and Daria Chudyka and Stephanie Hucke and Catharina Gro{\ss} and Frank Kurth and Christoph Leder and Karin Loser and Christian Kurts and Percy Knolle and Luisa Klotz and Heinz Wiendl",
note = "Copyright {\textcopyright} 2015 by The American Association of Immunologists, Inc.",
year = "2015",
month = oct,
day = "15",
doi = "10.4049/jimmunol.1402746",
language = "English",
volume = "195",
pages = "3584--3595",
journal = "Journal of immunology (Baltimore, Md. : 1950)",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "8",

}

RIS

TY - JOUR

T1 - B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway

AU - Herold, Martin

AU - Posevitz, Vilmos

AU - Chudyka, Daria

AU - Hucke, Stephanie

AU - Groß, Catharina

AU - Kurth, Frank

AU - Leder, Christoph

AU - Loser, Karin

AU - Kurts, Christian

AU - Knolle, Percy

AU - Klotz, Luisa

AU - Wiendl, Heinz

N1 - Copyright © 2015 by The American Association of Immunologists, Inc.

PY - 2015/10/15

Y1 - 2015/10/15

N2 - It is currently acknowledged that T H17 cells are critically involved in the pathogenesis of autoimmune diseases such as multiple sclerosis (MS). In this article, we demonstrate that signals delivered by the coinhibitory molecule B7-homologue 1 (B7-H1) via a B7-homologue 1 mouse-IgG2aFc (B7-H1-Ig) fusion protein nearly abolish T H17, but not T H1 and T H2, differentiation via direct interaction with the T cell. These effects were equally pronounced in the absence of programmed death-1 or B7.1 and B7.2 on the T cell side, thus providing clear evidence that B7-H1 modulates T cell differentiation via a novel receptor. Mechanistically, B7-H1 interfered with early TCR-mediated signaling and cytokine-mediated induction of the T H17-determining transcription factors retinoic acid-related orphan receptor g t and IFN regulator factor-4 in a programmed death-1 and B7-independent fashion. In an animal model of MS, active myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis, B7-H1-Ig exhibited a significant and long-lasting effect on disease severity upon administration during the first 5 d of the priming phase, which was accompanied by reduced T H17 responses in the periphery and within the CNS. Importantly, B7-H1-Ig was even capable of interfering with T cell encephalitogenicity when interaction with the T cells occurred after priming using an adoptive transfer experimental autoimmune encephalomyelitis model. In line with this, both naive human CD4 + T cells and differentiated T H17 effector cells from MS patients were highly sensitive toward B7-H1-Ig-mediated T H17 suppression. Together, we propose the existence of a novel B7-H1-mediated immune-regulatory pathway in T cells, which selectively limits murine and human T H17 cell responses and might be therapeutically exploited to control T H17-mediated autoimmunity.

AB - It is currently acknowledged that T H17 cells are critically involved in the pathogenesis of autoimmune diseases such as multiple sclerosis (MS). In this article, we demonstrate that signals delivered by the coinhibitory molecule B7-homologue 1 (B7-H1) via a B7-homologue 1 mouse-IgG2aFc (B7-H1-Ig) fusion protein nearly abolish T H17, but not T H1 and T H2, differentiation via direct interaction with the T cell. These effects were equally pronounced in the absence of programmed death-1 or B7.1 and B7.2 on the T cell side, thus providing clear evidence that B7-H1 modulates T cell differentiation via a novel receptor. Mechanistically, B7-H1 interfered with early TCR-mediated signaling and cytokine-mediated induction of the T H17-determining transcription factors retinoic acid-related orphan receptor g t and IFN regulator factor-4 in a programmed death-1 and B7-independent fashion. In an animal model of MS, active myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis, B7-H1-Ig exhibited a significant and long-lasting effect on disease severity upon administration during the first 5 d of the priming phase, which was accompanied by reduced T H17 responses in the periphery and within the CNS. Importantly, B7-H1-Ig was even capable of interfering with T cell encephalitogenicity when interaction with the T cells occurred after priming using an adoptive transfer experimental autoimmune encephalomyelitis model. In line with this, both naive human CD4 + T cells and differentiated T H17 effector cells from MS patients were highly sensitive toward B7-H1-Ig-mediated T H17 suppression. Together, we propose the existence of a novel B7-H1-mediated immune-regulatory pathway in T cells, which selectively limits murine and human T H17 cell responses and might be therapeutically exploited to control T H17-mediated autoimmunity.

KW - Chemistry

UR - http://www.scopus.com/inward/record.url?scp=84943545956&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1402746

DO - 10.4049/jimmunol.1402746

M3 - Journal articles

C2 - 26378076

VL - 195

SP - 3584

EP - 3595

JO - Journal of immunology (Baltimore, Md. : 1950)

JF - Journal of immunology (Baltimore, Md. : 1950)

SN - 0022-1767

IS - 8

ER -

DOI